Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG003 versus cetuximab or methotrexate in previously treated recurrent or metastatic head and neck squamous cell carcinoma
CTR20223356Phase 3Active
- Sponsor
- Hangzhou Miracogen
- Start
- Apr 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC), sponsored by Hangzhou Miracogen. Started Apr 2023; status: active.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20223356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223356.